Abstract:Objectives: Gestational trophoblastic neoplasia affects women of reproductive age and is usually treated by chemotherapy. Major concerns related to chemotherapy in young women are the possible infertility, risk of early menopause, and teratogenic effects on subsequent pregnancies. The study's aim was to analyze menstrual and reproductive outcomes of women treated with single-agent versus multiagent chemotherapy for gestational trophoblastic neoplasia. Methods: One-hundred fifty-one patients were treated. Seventy-six patients older than 45 years, with a placental site or epithelioid trophoblastic tumor, undergoing hysterectomy for patient choice, or undergoing human chorionic gonadotropin follow-up at the time of the analysis were excluded. Seventy-five patients were divided into subgroups according to International Federation of Gynecology and Obstetrics score: patients scoring less than 7, receiving single-agent chemotherapy (group A, n = 42); patients scoring 7 or greater, receiving combination treatment (group B, n = 33). Patients' outcomes were compared by univariate and multivariate analyses. Results: Temporary amenorrhea occurred in 33% of group A patients and 66.7% of group B (P = 0.01). Premature menopause occurred in 3 patients in group B (0% vs 9%, P = 0.02). Ten patients in group B underwent salvage hysterectomy. Pregnancy desire did not differ between the 2 groups (P = 0.555). In group A, 57.1% became pregnant; in group B, 36.4% did (P = 0.060). Instead, pregnancy rate was 52.2% among high-risk patients not undergoing hysterectomy (57.1% vs 52.2%, P = 0.449). There was no difference in miscarriage (P = 0.479) and premature birth (P = 0.615) rates. In a multivariate analysis that included age, International Federation of Gynecology and Obstetrics score, chemotherapy type, use of assisted reproductive technologies, previous pregnancies, and pregnancy desire, only age (P = 0.006) and pregnancy desire (P = 0.002) had a significant impact on the probability to have subsequent pregnancies. Conclusions: Except for the risk of premature ovarian failure, a rare adverse effect of combined treatments, both single-agent and multiagent chemotherapy can be safely administered to patients with a desire for childbearing. High-risk patients have worse reproductive outcomes because they undergo hysterectomy more frequently than low-risk patients.

The Effect of Prophylactic Chemotherapy on Treatment Outcome of Postmolar Gestational Trophoblastic Neoplasia

[Effects of Primary Chemotherapy with Single Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia and Influencing Factors Thereof].

[Curative Effects and Influenced Factors of Primary Chemotherapy with Single-Agent Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia].

Risk Factors for Methotrexate Resistance in Low-Risk Gestational Trophoblastic Neoplasia Patients (FIGO Score 0-4)

Comparison of Different Therapeutic Strategies for Complete Hydatidiform Mole in Women at Least 40 Years Old: a Retrospective Cohort Study.

[Single Methotrexate Chemotherapy for Low-Risk Gestational Trophoblastic Tumor].

The 16-Year Experience in Treating Low-Risk Gestational Trophoblastic Neoplasia Patients with Failed Primary Methotrexate Chemotherapy

Aneuploidy Rates and Clinical Pregnancy Outcomes after Preimplantation Genetic Testing for Aneuploidy Using the Progestin-Primed Ovarian Stimulation Protocol or the Gonadotropin-Releasing Hormone Antagonist Protocol

Clinical analysis of recurrent gestational trophoblastic neoplasia

Comparison of the multiples of the median of serum anti‐müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case–control study

Ema-Co Chemotherapy for High-Risk Gestational Trophoblastic Neoplasia: A Clinical Analysis of 54 Patients

Reproductive Outcomes After Gestational Trophoblastic Neoplasia. A Comparison Between Single-Agent and Multiagent Chemotherapy: Retrospective Analysis From the MITO-9 Group

Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia: a 19-year retrospective analysis

Diagnosis and management of or recurrent resistant gestational trophoblastic neoplasia

A Novel Prediction Model For Postmolar Gestational Trophoblastic Neoplasia And Comparison With Existing Models

Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial

Factors Predicting Severe Myelosuppression and Its Influence on Fertility in Patients with Low-Risk Gestational Trophoblastic Neoplasia Receiving Single-Agent Methotrexate Chemotherapy.

First-line monodrug chemotherapy in low-risk gestational trophoblastic neoplasia: a network meta-analysis

Total Hysterectomy Versus Uterine Evacuation for Preventing Post-Molar Gestational Trophoblastic Neoplasia in Patients Who Are at Least 40 Years Old: a Systematic Review and Meta-Analysis

Analysis of Clinical Characteristics and Outcomes in 7 Patients with Re-recurrent Gestational Trophoblastic Neoplasia.

The Efficacy and Safety of First-Line Single-Agent Chemotherapy Regimens in Low-Risk Gestational Trophoblastic Neoplasia: A Network Meta-Analysis.